Neurology Department 3, HanDan Central Hospital, Handan, China.
Department of Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
J Clin Lab Anal. 2022 May;36(5):e24372. doi: 10.1002/jcla.24372. Epub 2022 Mar 30.
Histone deacetylase 4 (HDAC4) is engaged in the pathophysiology of acute ischemic stroke (AIS) through modulating atherosclerosis, inflammation and neurocyte death. This study aimed to investigate the clinical role of HDAC4 in AIS.
Serum samples were collected from 176 AIS patients and 80 controls for HDAC4 detection by enzyme-linked immunosorbent assay (ELISA). In AIS patients, disease severity was assessed by National Institute of Health Stroke Scale (NIHSS) score and their recurrence-free survival (RFS) and overall survival (OS) were calculated, inflammatory cytokines and adhesion molecules were detected by ELISA.
HDAC4 was declined in AIS patients vs. controls (p < 0.001), it also had certain ability of distinguishing AIS patients from controls with an area under curve of 0.748 (95% confidence interval: 0.689-0.806). Among AIS patients, HDAC4 was negatively linked with NIHSS score (p < 0.001) but no other clinical features (all p > 0.05). Moreover, HDAC4 was negatively related to interleukin (IL)-17 (p = 0.010) and tumor necrosis factor alpha (p = 0.001), while it was not correlated with IL-1β (p = 0.081) or IL-6 (p = 0.074). Furthermore, HDAC4 was negatively associated with intercellular cell adhesion molecule-1 (p < 0.001) and vascular cell adhesion molecule-1 (p = 0.003). During a median follow-up of 19.0 months, 17 (9.7%) patients had recurrence and 10 (5.7%) patients died. Additionally, high HDAC4 was linked with prolonged RFS (p = 0.044) but not OS (p = 0.079).
HDAC4 possesses the potential to monitor disease risk, inflammation and estimate recurrence of AIS, while further study with larger scale is needed to verify our findings.
组蛋白去乙酰化酶 4（HDAC4）通过调节动脉粥样硬化、炎症和神经细胞死亡参与急性缺血性脑卒中（AIS）的病理生理学。本研究旨在探讨 HDAC4 在 AIS 中的临床作用。
通过酶联免疫吸附试验（ELISA）检测 176 例 AIS 患者和 80 例对照者的血清样本中 HDAC4 水平。采用美国国立卫生研究院卒中量表（NIHSS）评分评估 AIS 患者的疾病严重程度，计算其无复发生存率（RFS）和总生存率（OS），通过 ELISA 检测炎性细胞因子和黏附分子。
与对照组相比，AIS 患者的 HDAC4 水平降低（p<0.001），其曲线下面积（AUC）为 0.748（95%置信区间：0.689-0.806），具有一定的区分 AIS 患者和对照组的能力。在 AIS 患者中，HDAC4 与 NIHSS 评分呈负相关（p<0.001），但与其他临床特征均无相关性（均 p>0.05）。此外，HDAC4 与白细胞介素（IL）-17（p=0.010）和肿瘤坏死因子-α（p=0.001）呈负相关，而与 IL-1β（p=0.081）或 IL-6（p=0.074）无关。此外，HDAC4 与细胞间黏附分子-1（p<0.001）和血管细胞黏附分子-1（p=0.003）呈负相关。在中位随访 19.0 个月期间，17 例（9.7%）患者复发，10 例（5.7%）患者死亡。此外，高 HDAC4 与延长 RFS 相关（p=0.044），但与 OS 无关（p=0.079）。
HDAC4 具有监测疾病风险、炎症和评估 AIS 复发的潜力，还需要更大规模的研究来验证我们的发现。
